<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xml:lang="EN" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Infection</journal-id><journal-title>Infection</journal-title><issn pub-type="ppub">0300-8126</issn><issn pub-type="epub">1439-0973</issn><publisher><publisher-name>Urban &#x00026; Vogel</publisher-name><publisher-loc>Munich</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17565462</article-id><article-id pub-id-type="pmc">2782124</article-id><article-id pub-id-type="publisher-id">6068</article-id><article-id pub-id-type="doi">10.1007/s15010-007-6068-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Indinavir/Low-dose Ritonavir Containing HAART in HIV-1 Infected Children has Potent Antiretroviral Activity, but is Associated with Side Effects and Frequent Discontinuation of Treatment</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Fraaij</surname><given-names>P. L. A.</given-names></name><address><phone>(+31/10) 463-6104</phone><fax>(+31/10) 463-6449</fax><email>p.fraaij@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Verweel</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Rossum</surname><given-names>A. M. C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hartwig</surname><given-names>N. G.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burger</surname><given-names>D. M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Groot</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Dept. of Pediatrics, Erasmus MC-Sophia Children&#x02019;s Hospital, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands </aff><aff id="Aff2"><label>2</label>Dept. of Clinical Pharmacy and Nijmegen University Center for Infectious Diseases (NUCI), University Medical Center, Nijmegen, The Netherlands </aff><aff id="Aff3"><label>3</label>Dept. of Pediatrics and Nijmegen University Center for Infectious Diseases (NUCI), University Medical Center, Nijmegen, The Netherlands </aff></contrib-group><pub-date pub-type="ppub"><month>6</month><year>2007</year></pub-date><volume>35</volume><issue>3</issue><fpage>186</fpage><lpage>189</lpage><history><date date-type="received"><day>14</day><month>3</month><year>2006</year></date><date date-type="accepted"><day>20</day><month>12</month><year>2006</year></date></history><permissions><copyright-statement>&#x000a9; Urban &#x00026; Vogel M&#x000fc;nchen 2007</copyright-statement></permissions><abstract xml:lang="EN"><title><bold>Abstract</bold></title><p>We here present the study results of 21 HIV-1 infected children who were treated with indinavir plus low-dose ritonavir and two nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. Although this q12h HAART regimen had potent antiretroviral activity, it was frequently associated with side effects and discontinuation of therapy.</p></abstract><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Urban &#x00026; Vogel M&#x000fc;nchen 2007</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Indinavir is a potent protease inhibitor (PI), which has successfully been used in adults and children in combination with nucleoside reverse transcriptase inhibitors (NRTIs) to suppress HIV-1 infection [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Durable suppression of HIV requires good adherence to the HAART regimen. Discontinuation or irregular use of HAART results in viral rebound, resistance of HIV to the medication and ultimately AIDS [<xref ref-type="bibr" rid="CR3">3</xref>]. HAART regimens containing indinavir are difficult to adhere to. Indinavir, when used as a sole PI, must be administered three times daily (q8h), thus interfering with the sleeping time and school hours of children. In addition, food restrictions further complicate the regimen, since the drug needs to be taken on an empty stomach or with a low-caloric meal.</p><p>To ensure adherence to an indinavir-containing HAART regimen, less frequent and less complicated dosing schemes are required. An addition of low-dose ritonavir to indinavir increases plasma levels of indinavir allowing for a twice-daily medication scheme without the necessity for food restrictions [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Currently, no information on the long-term clinical efficacy and safety of this combination in children is available. Therefore, we performed an open uncontrolled pilot study in 21 HIV-1 infected children who were treated with indinavir and low-dose ritonavir containing HAART.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><p>Children included in the Rotterdam cohort and treated with q8h-dosed HAART with indinavir as the sole PI were offered to change therapy to q12h-dosed HAART with indinavir and low-dose ritonavir [<xref ref-type="bibr" rid="CR6">6</xref>]. In addition, between 2001 and 2002, HAART-containing indinavir and low-dose ritonavir were initiated in children naive to antiretroviral medication with a mean HIV RNA level &#x0003e; 5.000 copies/ml and a CD4+ T-cell count below age-specific reference values. The study protocol was approved by the medical ethical committee of the Erasmus MC. Written and informed consent was obtained from parents and patients. The patients&#x02019; medical histories, physical examinations and laboratory values were analyzed before the start of the medication and after 4, 8, 12, 24, 36 and 48 weeks of treatment. After minimally 2 weeks of treatment, the steady-state pharmacokinetics of indinavir was determined [<xref ref-type="bibr" rid="CR7">7</xref>]. This procedure was repeated when dosage adjustment of indinavir was necessary to normalize the area under the plasma concentration-time curve (AUC) to adult values.</p><p>Age-specific reference values for the CD4+ T-cells were calculated by dividing the patient&#x02019;s individual value at the different time points by the median of the reference value at the different time points [<xref ref-type="bibr" rid="CR8">8</xref>]. Differences between paired variables were analyzed with the Wilcoxon-signed rank test and between groups with the Mann-Whitney U-test. For statistical analysis of the data, SPSS&#x000a9;12 and Microsoft Excel&#x000a9;97 software were used.</p></sec><sec id="Sec3" sec-type="results"><title>Results</title><p>A total of 21 children were enrolled in the study of which 16 completed the 48 weeks study period. The baseline characteristics of all patients are summarized in table <xref rid="Tab1" ref-type="table">1</xref>. Four children were naive to antiretroviral therapy (Group A). Seventeen children had received prior indinavir-containing HAART for a median period of 18 months (range, 2-50 months). Of these, nine had baseline HIV-1 RNA levels below 500 copies/ml (Group B1) and eight had HIV-1 RNA levels above 500 copies/ml (Group B2). Indinavir was started at a median dosage of 400 mg/m<sup>2</sup> (range 300&#x02013;600) and ritonavir was started at a median dosage of 125 mg/m2 (range 100&#x02013;125).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of the 21 children.</p></caption><table frame="hsides" rules="groups"><thead><tr><th><italic>Characteristics:</italic></th><th/></tr></thead><tbody><tr><td>Sex (male/female)</td><td>7/14</td></tr><tr><td>Ethnicity (white/non-white)</td><td>2/19</td></tr><tr><td>Age in years<sup>a</sup></td><td>7 (0.4&#x02013;6.3)</td></tr><tr><td><italic>Route of infection:</italic></td><td/></tr><tr><td>Vertical</td><td>15</td></tr><tr><td>Blood products</td><td>3</td></tr><tr><td>Unknown</td><td>3</td></tr><tr><td><italic>CDC classification</italic><sup>c</sup>:</td><td/></tr><tr><td>N1: 1; N2: 3; N3: 2</td><td/></tr><tr><td>A1: &#x02212; A2: 3; A3: 3</td><td/></tr><tr><td>B1: &#x02212; B2: 5; B3: &#x02212;</td><td/></tr><tr><td>C1: &#x02212; C2: 2; C3: 2</td><td/></tr><tr><td><italic>Treatment history:</italic></td><td/></tr><tr><td>Na&#x000ef;ve to HAART (Group A)</td><td>4</td></tr><tr><td>Pretreated with PI containing</td><td/></tr><tr><td>HAART, HIV RNA &#x0003c; 500 copies/ml</td><td>9</td></tr><tr><td>(Group B1)</td><td/></tr><tr><td>Pretreated with PI-containing</td><td/></tr><tr><td>HAART, HIV RNA &#x0003e; 500 copies/ml</td><td>8</td></tr><tr><td>(Group B2)</td><td/></tr><tr><td><italic>Baseline HIV-1 RNA levels</italic><sup>b</sup><italic>(copies/ml):</italic></td><td/></tr><tr><td>Group A</td><td>168,750 (48,975&#x02013;89,500)</td></tr><tr><td>Group B2</td><td>4,650 (2,360&#x02013;4,794)</td></tr><tr><td><italic>PI dosage</italic><sup>b</sup>:</td><td/></tr><tr><td>Indinavir (mg/m<sup>2</sup>)</td><td>400 (300&#x02013;00)</td></tr><tr><td>Ritonavir (mg/m<sup>2</sup>)</td><td>125 (100&#x02013;25)</td></tr><tr><td><italic>NRTI backbone:</italic></td><td/></tr><tr><td>AZT/3TC, q12h</td><td>20</td></tr><tr><td>ddI/d4T, 12h</td><td>1</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Median (range); <sup>b</sup> Median interquartile range (IQR); <sup>c</sup> CDC classification as defined by the US Centers for Disease Control, scored from the day of diagnosis onwards</p></table-wrap-foot></table-wrap></p><p>The clinical condition of the patients during the study period was good. None of the patients showed signs and symptoms of AIDS and no progression in their CDC-classification stage was observed. The course of the surrogate markers viral load and CD4 + T-cell counts during the follow- up are depicted in table <xref rid="Tab2" ref-type="table">2</xref>. Overall after 48 weeks of treatment 13 out of the 16 children still on treatment had HIV-1 RNA levels &#x0003c; 500 copies/ml and 11 &#x0003c; 50 copies/ml. In Group A, three out of four patients had HIV-1 RNA levels &#x0003c; 50 copies after 48 weeks of treatment. In Group B1, seven out of eight patients had HIV-1 RNA levels &#x0003c; 50 copies. In Group B2, three of four children had HIV-1 RNA levels &#x0003c; 500 copies/ml, but only 1 had HIV-1 RNA levels &#x0003c; 50 copies/ml. Over time an increase in CD4 + T-cells was observed, albeit not significant for any treatment group. (p-value baseline vs week 48 for the total group CD4% total T-cells 0.234 and for CD4% normal 0.14).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Clinical en immunological parameters during 1-year follow-up of 21 children treated with indinavir/ritonavir.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th><bold>Week 0</bold></th><th><bold>Week 12</bold></th><th><bold>Week 24</bold></th><th><bold>Week 36</bold></th><th><bold>Week 48</bold></th></tr></thead><tbody><tr><td><italic>Total Group:</italic></td><td/><td/><td/><td/><td/></tr><tr><td>On treatment</td><td>21</td><td>18</td><td>16</td><td>16</td><td>16</td></tr><tr><td>HIV-1 RNA levels &#x0003c; 500</td><td>9 (43%)</td><td>13 (72%)</td><td>13 (81%) 14</td><td>14 (88%)</td><td>13 (81%)</td></tr><tr><td>HIV-1 RNA levels &#x0003c; 50</td><td>6 (29%)</td><td>8 (44%)</td><td>10 (63%)</td><td>11 (69%)</td><td>11 (69%))</td></tr><tr><td>Median %CD4<sup>a</sup></td><td>37 (23&#x02013;54)</td><td>40 (32&#x02013;61)</td><td>41 (35&#x02013;61)</td><td>40 (32&#x02013;62)</td><td>40 (30&#x02013;62)</td></tr><tr><td>Median CD4% normal<sup>a</sup></td><td>61 (38&#x02013;105)</td><td>72 (47&#x02013;117)</td><td>78 (55&#x02013;122)</td><td>67 (57&#x02013;135)</td><td>68 (54&#x02013;128)</td></tr><tr><td><italic>Group A:</italic></td><td/><td/><td/><td/><td/></tr><tr><td>On treatment</td><td>4</td><td>4</td><td>4</td><td>4</td><td>4</td></tr><tr><td>HIV-1 RNA levels &#x0003c; 500</td><td>0</td><td>3 (75%)</td><td>4 (100%)</td><td>3 (75%)</td><td>3 (75%)</td></tr><tr><td>HIV-1 RNA levels &#x0003c; 50</td><td>0</td><td>1 (25%)</td><td>2 (50%)</td><td>3 (75%)</td><td>3 (75%)</td></tr><tr><td>Median %CD4 <sup>a</sup></td><td>28 (7&#x02013;41)</td><td>39 (15&#x02013;46)</td><td>38 (26&#x02013;58)</td><td>36 (21&#x02013;56)</td><td>40 (26&#x02013;58)</td></tr><tr><td>Median CD4% normal<sup>a</sup></td><td>39 (8&#x02013;123)</td><td>45 (27&#x02013;95)</td><td>71 (42&#x02013;149)</td><td>61 (49&#x02013;115)</td><td>57 (42&#x02013;139)</td></tr><tr><td><italic>Group B1:</italic></td><td/><td/><td/><td/><td/></tr><tr><td>On treatment</td><td>9</td><td>8</td><td>8</td><td>8</td><td>8</td></tr><tr><td>HIV-1 RNA levels &#x0003c; 500</td><td>9 (100%)</td><td>6 (75%)</td><td>8 (100%)</td><td>8 (100%)</td><td>7 (88%)</td></tr><tr><td>HIV-1 RNA levels &#x0003c; 50</td><td>6 (67%)</td><td>6 (75%)</td><td>8 (100%)</td><td>6 (75%)</td><td>7 (88%)</td></tr><tr><td>Median %CD4<sup>a</sup></td><td>45 (38&#x02013;48)</td><td>46 (38&#x02013;59)</td><td>43 (37&#x02013;53)</td><td>42 (37&#x02013;57)</td><td>40 (32&#x02013;56)</td></tr><tr><td>Median CD4% normal<sup>a</sup></td><td>96 (60&#x02013;118)</td><td>76 (69&#x02013;134)</td><td>78 (67&#x02013;126)</td><td>87 (58&#x02013;141)</td><td>80 (57&#x02013;121)</td></tr><tr><td><italic>Group B2:</italic></td><td/><td/><td/><td/><td/></tr><tr><td>On treatment</td><td>8</td><td>7</td><td>4</td><td>4</td><td>4</td></tr><tr><td>HIV-1 RNA levels &#x0003c; 500</td><td>0</td><td>4 (75%)</td><td>1 (25%)</td><td>3 (75%)</td><td>3 (75%)</td></tr><tr><td>HIV-1 RNA levels &#x0003c; 50</td><td>0</td><td>1 (15%)</td><td>0</td><td>2 (50%)</td><td>1 (25%)</td></tr><tr><td>Median %CD4<sup>a</sup></td><td>24 (19&#x02013;46)</td><td>33 (29&#x02013;61)</td><td>34 (22&#x02013;53)</td><td>40 (27&#x02013;53)</td><td>41 (25&#x02013;52)</td></tr><tr><td>Median CD4% normal<sup>a</sup></td><td>53 (27&#x02013;68)</td><td>69 (51&#x02013;124)</td><td>83 (48&#x02013;122)</td><td>100 (54&#x02013;143)</td><td>90 (49&#x02013;205)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Median (interquartile range). Group A: children naive to HAART, Group B1: PI experienced patients with HIV-1; RNA &#x0003c; 500 copies on baseline, Group B2: PI experienced patients with HIV-1 RNA &#x0003e; 500 copies on baseline</p></table-wrap-foot></table-wrap></p><p>Most children (n = 19) reported side effects related to the medication. The adverse events occurred throughout the entire study period. These side effects were often mild and of gastrointestinal origin. However, serious adverse were reported in seven children. These included nephrolithiasis (n = 2), silent nephrolithiasis found upon ultrasound research (n = 2), jaundice (n = 1), impaired liver functions, vomiting and malaise (n = 1) and dehydration due to vomiting (n = 1). Serious side effects were observed in all study groups (Group A: 1, Group B1: 3 and B2: 3) (Table <xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>No significant difference in the occurrence of SAE&#x02019;s between the three treatment groups: NPar tests occurrence of SAE&#x02019;s <italic>&#x003c7;</italic><sup>2</sup>-test frequencies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Observed N</th><th>Expected N</th><th>Residual</th></tr></thead><tbody><tr><td><italic>Group A</italic></td><td/><td/><td/></tr><tr><td>SAE</td><td>1</td><td>2.0</td><td>1.0</td></tr><tr><td>No SAE</td><td>3</td><td>2.0</td><td>1.0</td></tr><tr><td>Total</td><td>4</td><td/><td/></tr><tr><td><italic>Group B1</italic></td><td/><td/><td/></tr><tr><td>SAE</td><td>3</td><td>4.5</td><td>1.5</td></tr><tr><td>No SAE</td><td>6</td><td>4.5</td><td>1.5</td></tr><tr><td>Total</td><td>9</td><td/><td/></tr><tr><td><italic>Group B2</italic></td><td/><td/><td/></tr><tr><td>SAE</td><td>3</td><td>4.0</td><td>1.0</td></tr><tr><td>No SAE</td><td>5</td><td>4.0</td><td>1.0</td></tr><tr><td>Total</td><td>8</td><td/><td/></tr><tr><td><italic>Test statistics</italic></td><td>Group A</td><td>Group B1</td><td>Group B2</td></tr><tr><td><italic>&#x003c7;</italic><sup>2 a,b</sup></td><td>1.000</td><td>1.000</td><td>0.500</td></tr><tr><td>Df</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Asymp. Sig.</td><td>0.317</td><td>0.317</td><td>0.480</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> 2 cells (100.0%) have expected frequencies less than 5. The minimum expected cell frequency is 2.0; <sup>b</sup> 2 cells (100.0%) have expected frequencies less than 5. The minimum expected cell frequency is 4.5; <sup>c</sup> 2 cells (100.0%) have expected frequencies less than 5. The minimum expected cell frequency is 4.0</p></table-wrap-foot></table-wrap></p><p>Five patients stopped therapy during the follow-up period. In one additional patient medication was discontinued on the last study day. Discontinuation happened four times because of drug toxicity (1 nephrolithiasis, 1 silent nephrolithiasis, 1 rash, 1 hepatitis) and twice on patient request. All children that stopped medication were pretreated and most (n = 4) had detectable viral loads at the start of the study. These patients had suffered from indinavir related toxicity in the past. However, none of the adverse events that had occurred before the start of the study were serious (Table <xref rid="Tab4" ref-type="table">4</xref>).
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Study termination and viral load at start of the study: NPar tests <italic>&#x003c7;</italic><sup>2</sup>-test frequencies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Observed N</th><th>Expected N</th><th>Residual</th></tr></thead><tbody><tr><td><italic>Group B1</italic></td><td/><td/><td/></tr><tr><td>Terminated study medication</td><td>2</td><td>4.5</td><td>2.5</td></tr><tr><td>Did not terminate study medication</td><td>7</td><td>4.8</td><td>2.5</td></tr><tr><td>Total</td><td>9</td><td/><td/></tr><tr><td><italic>Group B2</italic></td><td/><td/><td/></tr><tr><td>Terminated study medication</td><td>4</td><td>4.0</td><td>0.0</td></tr><tr><td>Did not terminate study medication</td><td>4</td><td>4.0</td><td>0.0</td></tr><tr><td>Total</td><td>8</td><td/><td/></tr><tr><td><italic>Test statistics</italic></td><td>Group B1</td><td>Group B2</td><td/></tr><tr><td><italic>&#x003c7;</italic><sup>2 a,b</sup></td><td>2.778</td><td>0.000</td><td/></tr><tr><td>Df</td><td>1</td><td>1</td><td/></tr><tr><td>Asymp. Sig.</td><td>0.096</td><td>1.000</td><td/></tr></tbody></table><table-wrap-foot><p><sup>a</sup> 2 cells (100.0%) have expected frequencies less than 5. The minimum expected cell frequency is 4.5; <sup>b</sup> 2 cells (100.0%) have expected frequencies less than 5. The minimum expected cell frequency is 4.0</p></table-wrap-foot></table-wrap></p><p>No significant differences were found between the PK parameters of children with or without side effects (data not shown). However, in two children renal side effects resolved after a decrease of the indinavir or ritonavir dosage. In the four children who discontinued medication because of side effects dosage adjustments were not performed. This was because of the seriousness of the side effects and hesitation in the patients and their parents to restart indinavir.</p></sec><sec id="Sec4" sec-type="discussion"><title>Discussion</title><p>The studied regimen had potent antiretroviral activity with suppression of HIV in most children who remained on therapy for 1 year. However, side effects occurred frequently. No clear relation between the height of PK parameters and side effects or discontinuation of therapy were found. Still, most children in our study received indinavir/ritonavir 400/125 mg/m<sup>2</sup> q12h which has been shown to result in significantly higher indinavir exposure compared to reference data of indinavir q8h in both adults and children [<xref ref-type="bibr" rid="CR7">7</xref>]. This increased AUC may result in a higher incidence of side effects, especially when instructions to increase fluid intake are not sufficiently followed. This is of major concern since the occurrence of side effects poses a major threat to the adherence, whilst maintenance of adherence was the most important reason to perform this medication change. In addition, patients reported that the combination was not easy to take: the high pill burden and the bad taste of ritonavir liquid were considered as negative aspects of the new regimen. Side effects and intolerance to the medication resulted in a high number of children that discontinued the study regimen as compared to studies in children with new and easier to use HAART regimens. In a study on lopinavir/ritonavir-containing HAART in children only 2 out of 100 patients prematurely discontinued treatment [<xref ref-type="bibr" rid="CR9">9</xref>]. However, one should be cautious to compare both studies, since the numbers of patients are relatively small and the studied patient population selected differently. Interestingly, a large proportion of children that discontinued medication in our study had detectable viral loads at baseline. Possibly, preexisting problems with adherence may have influenced our data: As a result of non-adherence plasma levels tent to fluctuate, which may induce side effects [<xref ref-type="bibr" rid="CR10">10</xref>]. In addition non-adherent patients are more likely to be less motivated to continue medication and thus terminate study participation.</p><p>Because of the high number of side effects and patients that prematurely discontinued medication, we feel that newer and easier to use HAART regimens than indinavir/low-dose ritonavir should be used to treat HIV-1 infected children. However when these are not available indinavir combined with ritonavir can be considered as a treatment option for HIV-1 infected children.</p></sec><sec id="Sec5"><title>Financial Disclosure</title><p>The authors have participated in studies that were financially supported by Merck Sharp and Dome, GlaxoSmithKline and the Aids Fonds, The Netherlands from 1997 to 1999. From 2002 until 2003, the studies received financial support from Merck Sharp and Dome, GlaxoSmithKline and Abbott. No other associations of the authors are reported that might pose a conflict of interest. There was no involvement of the previously mentioned sponsors in data collection, data analysis, the writing of this article, and article submission.</p></sec></body><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossum</surname><given-names>A.M.</given-names></name><name><surname>Geelen</surname><given-names>S.P.</given-names></name><name><surname>Hartwig</surname><given-names>N.G.</given-names></name><name><surname>Wolfs</surname><given-names>T.F.</given-names></name><name><surname>Weemaes</surname><given-names>C.M.</given-names></name><name><surname>Scherpbier</surname><given-names>H.J.</given-names></name><etal/></person-group><article-title>Results of 2 years of treatment with protease- inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1</article-title><source>Clin Infect Dis</source><year>2002</year><volume>34</volume><fpage>1008</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1086/339443</pub-id></citation><citation citation-type="display-unstructured">van Rossum AM, Geelen SP, Hartwig NG, Wolfs TF, Weemaes CM, Scherpbier HJ, et al.: Results of 2 years of treatment with protease- inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002;34:1008&#x02013;1016. <pub-id pub-id-type="pmid">11880968</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gulick</surname><given-names>R.M.</given-names></name><name><surname>Mellors</surname><given-names>J.W.</given-names></name><name><surname>Havlir</surname><given-names>D.</given-names></name><name><surname>Eron</surname><given-names>J.J.</given-names></name><name><surname>Meibohm</surname><given-names>A.</given-names></name><name><surname>Condra</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine</article-title><source>Ann Intern Med</source><year>2000</year><volume>133</volume><fpage>35</fpage><lpage>39</lpage></citation><citation citation-type="display-unstructured">Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al.: 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000;133:35&#x02013;39. <pub-id pub-id-type="pmid">10877738</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>S.G.</given-names></name></person-group><article-title>Treatment of antiretroviral-drug-resistant HIV-1 infection</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>2002</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)15022-2</pub-id></citation><citation citation-type="display-unstructured">Deeks SG: Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003;362:2002&#x02013;2011. <pub-id pub-id-type="pmid">14683662</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>A.</given-names></name><name><surname>Granneman</surname><given-names>G.R.</given-names></name><name><surname>Cao</surname><given-names>G.</given-names></name><name><surname>Carothers</surname><given-names>L.</given-names></name><name><surname>Japour</surname><given-names>A.</given-names></name><name><surname>El-Shourbagy</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers</article-title><source>Antimicrob Agents Chemother</source><year>1998</year><volume>42</volume><fpage>2784</fpage><lpage>2791</lpage></citation><citation citation-type="display-unstructured">Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, et al.: Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998;42:2784&#x02013;2791. <pub-id pub-id-type="pmid">9797204</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossum</surname><given-names>A.M.</given-names></name><name><surname>Groot</surname><given-names>R.</given-names></name><name><surname>Hartwig</surname><given-names>N.G.</given-names></name><name><surname>Weemaes</surname><given-names>C.M.</given-names></name><name><surname>Head</surname><given-names>S.</given-names></name><name><surname>Burger</surname><given-names>D.M.</given-names></name></person-group><article-title>Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection</article-title><source>AIDS</source><year>2000</year><volume>14</volume><fpage>2209</fpage><lpage>2210</lpage><pub-id pub-id-type="doi">10.1097/00002030-200009290-00022</pub-id></citation><citation citation-type="display-unstructured">van Rossum AM, de Groot R, Hartwig NG, Weemaes CM, Head S, Burger DM: Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection. AIDS 2000;14:2209&#x02013;2210. <pub-id pub-id-type="pmid">11061667</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>D.M.</given-names></name><name><surname>Rossum</surname><given-names>A.M.</given-names></name><name><surname>Hugen</surname><given-names>P.W.</given-names></name><name><surname>Suur</surname><given-names>M.H.</given-names></name><name><surname>Hartwig</surname><given-names>N.G.</given-names></name><name><surname>Geelen</surname><given-names>S.P.</given-names></name><etal/></person-group><article-title>Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children</article-title><source>Antimicrob Agents Chemother</source><year>2001</year><volume>45</volume><fpage>701</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1128/AAC.45.3.701-705.2001</pub-id></citation><citation citation-type="display-unstructured">Burger DM, van Rossum AM, Hugen PW, Suur MH, Hartwig NG, Geelen SP, et al.: Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 2001;45:701&#x02013;705. <pub-id pub-id-type="pmid">11181346</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergshoeff</surname><given-names>A.S.</given-names></name><name><surname>Fraaij</surname><given-names>P.L.</given-names></name><name><surname>Rossum</surname><given-names>A.M.</given-names></name><name><surname>Verweel</surname><given-names>G.</given-names></name><name><surname>Wynne</surname><given-names>L.H.</given-names></name><name><surname>Winchell</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children</article-title><source>Antimicrob Agents Chemother</source><year>2004</year><volume>48</volume><fpage>1904</fpage><lpage>1907</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.5.1904-1907.2004</pub-id></citation><citation citation-type="display-unstructured">Bergshoeff AS, Fraaij PL, van Rossum AM, Verweel G, Wynne LH, Winchell GA, et al.: Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 2004;48:1904&#x02013;1907. <pub-id pub-id-type="pmid">15105157</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Comans-Bitter</surname><given-names>W.M.</given-names></name><name><surname>Groot</surname><given-names>R.</given-names></name><name><surname>Beemd</surname><given-names>R.</given-names></name><name><surname>Neijens</surname><given-names>H.J.</given-names></name><name><surname>Hop</surname><given-names>W.C.</given-names></name><name><surname>Groeneveld</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations</article-title><source>J Pediatr</source><year>1997</year><volume>130</volume><fpage>388</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(97)70200-2</pub-id></citation><citation citation-type="display-unstructured">Comans-Bitter WM, de Groot R, van den Beemd R, Neijens HJ, Hop WC, Groeneveld K, et al.: Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997;130:388&#x02013;393. <pub-id pub-id-type="pmid">9063413</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saez-Llorens</surname><given-names>X.</given-names></name><name><surname>Violari</surname><given-names>A.</given-names></name><name><surname>Deetz</surname><given-names>C.O.</given-names></name><name><surname>Rode</surname><given-names>R.A.</given-names></name><name><surname>Gomez</surname><given-names>P.</given-names></name><name><surname>Handelsman</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children</article-title><source>Pediatr Infect Dis J</source><year>2003</year><volume>22</volume><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1097/00006454-200303000-00003</pub-id></citation><citation citation-type="display-unstructured">Saez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, Handelsman E, et al.: Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003;22:216&#x02013;224. <pub-id pub-id-type="pmid">12634581</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fraaij</surname><given-names>P.L.</given-names></name><name><surname>Kampen</surname><given-names>J.J.</given-names></name><name><surname>Burger DM de Groot</surname><given-names>R.</given-names></name></person-group><article-title>Pharmacokinetics of antiretroviral therapy in HIV-1-infected children</article-title><source>Clin Pharmacokinet</source><year>2005</year><volume>44</volume><fpage>935</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.2165/00003088-200544090-00004</pub-id></citation><citation citation-type="display-unstructured">Fraaij PL, van Kampen JJ, Burger DM de Groot R: Pharmacokinetics of antiretroviral therapy in HIV-1-infected children. Clin Pharmacokinet. 2005;44:935&#x02013;956. <pub-id pub-id-type="pmid">16122281</pub-id></citation></ref></ref-list></back></article>


